Apellis Pharmaceuticals, Inc. (APLS): Rasio rega marang dodolan

The price-to-sales ratio on the GURU.Markets chart illustrates the valuation trend, where the parameter value equals 4.80 for Apellis Pharmaceuticals (APLS). The development of various therapeutic platforms reduces reliance on a single market. However, geopolitical fragmentation hinders biotechnology exports and international research. Meanwhile, business stability relies on sales of the macular degeneration drug amid moderate revenue growth.

For Apellis Pharmaceuticals (APLS), which is rebuilding physician trust following safety crises, market valuation often outpaces the actual commercial success of its drugs. The current price-to-sales ratio measures the premium investors are willing to pay for every dollar of sales; sharp deviations on the chart signal speculative overheating of the asset relative to its actual cash inflows, creating a risk of capital correction.